SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

Inclusion Criteria:

* Lung Cancer Small cell histologically confirmed.
* SCLC stage IV according to the TNM classification in 2009
* Relapse localized SCLC treated with chemoradiotherapy if they are outside the radiation field.
* Patients who have had an objective response to first-line chemotherapy with cisplatin and etoposide or carboplatin and etoposide and have a time interval \> or = 90 days between relapse and first-line chemotherapy (the date is set J1 of the last cycle)
* At least one-dimensionally measurable disease (RECIST)
* Age \> or = 18 years
* Weight loss \<10% during the last 3 months
* Performance status (PS) \< or = 2
* Creatinine clearance\> 45 ml / min.
* Neutrophils \>1,5X10 9 / L and platelets \> 100X109 / L.
* Bilirubin \< 1,5 X normal.
* Transaminases, alkaline phosphatase \< 2,5 X normal except in cases of hepatic metastases (5 X normal).
* Informed Consent signed
* Patients with asymptomatic brain metastases may be included
* Prophylactic brain irradiation based on the habits of each center defined in advance

Exclusion Criteria:

* Lung cancer non-small cell or mixed form (small cell / non-small cell) or absence of histological evidence
* SCLC stage I or stage II or stage III.
* Patients who have not had an objective response to first-line chemotherapy with cisplatin and etoposide or carboplatin and etoposide or that have a time interval \< 90 days between relapse and first-line chemotherapy (the date is defined in J1 of the last cycle)
* Serum Na \< 125 mmol / L
* Hypercalcemia despite corrective treatment
* Brain metastases or symptomatic meningeal
* A history of malignancy within the last 5 years with the exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix.
* Other concomitant serious medical conditions: congestive heart failure, unstable angina, significant arrhythmia or previous myocardial in the previous six months trial
* Severe or uncontrolled systemic diseases, the investigator found incompatible with the proposed protocol
* Neurological and psychiatric disorders prohibiting comprehension test
* Severe infectious disease during or fever \> 38 ° C
* Peripheral neuropathy \> or = grade 2
* Any geographical or psychological condition does not allow a proper understanding and compliance with the protocol.
* Private Patient freedom following a judicial or administrative decision
* Pregnant woman, parturient or nursing; Women of childbearing potential and men with a woman of childbearing age must have adequate contraception for the duration of the study and up to 6 months after treatment ends.
* Patient in an exclusion period for another Biomedical study